Moleculin Biotech, Inc. Banner Image

Moleculin Biotech, Inc.

  • Ticker MBRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Moleculin Biotech, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for theMore treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related antimetabolite compounds capable of Metabolism/Glycosylation Inhibition.
4.8 / 5.0 (354)

Moleculin Biotech, Inc. reports have an aggregate usefulness score of 4.8 based on 354 reviews.

Moleculin Biotech, Inc.

Most Recent Annual Report

Moleculin Biotech, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Moleculin Biotech, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!